RTW Investments has a series C for the UT Southwestern and Gladstone Institutes spinout, which will progress its lead asset into the clinic.

Tenaya Therapeutics, a US-based developer of therapies for heart disease exploiting Gladstone Institutes and University of Texas Southwestern Medical Center research, collected $106m in a series C round yesterday led by RTW Investments.
GV, a corporate venturing arm of technology conglomerate Alphabet, also took part in the round, as did RA Capital Management, Fidelity, Column Group, Casdin Capital, funds and accounts advised by T Rowe Price Associates and all other existing shareholders.
Founded in 2016, Tenaya’s approach to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in